LKT Labs

Biochemicals for Life Science Research

Belinostat

Belinostat

Product ID B1746
Cas No. 414864-00-9
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $127.00 In stock
10 mg $194.00 In stock
Bulk Quote

Quicklinks

Description

Belinostat is a histone deacetylase (HDAC) inhibitor that exhibits antiviral and anticancer chemotherapeutic activities. Belinostat is approved for use in humans in the treatment of T cell lymphoma and is currently in clinical trials as a potential treatment for other leukemias and lymphomas. In pancreatic cancer cells, belinostat induces apoptosis in an AMPK-dependent manner. In other cellular models, this compound decreases HIV release from macrophages by degrading intracellular HIV.

Product Info

Cas No.

414864-00-9
Purity

≥98%
Formula

C15H14N2O4S
Formula Wt.

318.35
IUPAC Name

(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
Synonym

PXD101
Solubility

DMSO 64 mg/mL (201.03 mM) Water Insoluble Ethanol Insoluble
Appearance

Pale yellow powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

B1746 MSDS PDF
Info Sheet

B1746 Info Sheet PDF

References

Campbell GR, Bruckman RS, Chu YL, et al. Autophagy Induction by Histone Deacetylase Inhibitors Inhibits HIV Type 1. J Biol Chem. 2015 Feb 20;290(8):5028-40. PMID: 25540204.

Foss F, Advani R, Duvic M, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2014 Nov 17. [Epub ahead of print].
PMID: 25404094.

Kirschbaum MH, Foon KA, Frankel P, et al. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma. 2014 Oct;55(10):2301-4. PMID: 24369094.

Wang B, Wang XB, Chen LY, et al. Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involve activation of TAK1-AMPK signaling axis. Biochem Biophys Res Commun. 2013 Jul 19;437(1):1-6. PMID: 23743198.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • S6134

    Spinorphin, bovine

    Endogenous heptapeptide; P2X3 and N-formylpepti...

    ≥95%
  • C7992

    CTX-0294885

    Bisaniline pyrimidine; pan-kinase inhibitor.

    ≥98%
  • U682040

    URB597

    FAAH inhibitor.

    ≥98%
  • S760004

    Stachybotrylactam

    Spirodihydrobenzofuranlactam

    ≥98%
  • D1774

    Desloratadine

    Loratadine metabolite; FIASMA, histamine H1 ant...

    ≥97%
  • R3449

    Rimonabant Hydrochloride

    CB1 inverse agonist.

    ≥98%
  • M4652

    MLN8237

    AurKA inhibitor.

    ≥98%
  • L589940

    LOXO-101

    Inhibitor of tropomyosin kinase receptors TRKA,...

    ≥99%
  • N5986

    Novobiocin Sodium

    Aminocoumarin; bacterial DNA gyrase inhibitor.<...

    ≥98%
  • G7241

    GSK-461364

    PLK1 inhibitor.

    ≥99%
  • S5722

    Sofosbuvir

    Viral RNA polymerase inhibitor.

    ≥98%
  • R0161

    Rapamycin

    Macrolide originally produced by Streptomyces; ...

    ≥99%
  • G7340

    GSK-126

    EZH2 HMT inhibitor.

    ≥98%, ≥99%ee
  • L1628

    Ac-LEHD-pNa

    Caspase 9 substrate.

    ≥95%
  • S6800

    SR1001

    RORα/γ inverse agonist.

    ≥99%
  • L0211

    Lactulose

    Synthetic non-digestible disaccharide.

    ≥99%
  • S8014

    Substance P, Free Acid

    Endogenous tachykinin peptide, involved in infl...

    ≥95%
  • A5160

    Ampicillin Trihydrate

    β-lactam; transpeptidase inhibitor.

    ≥97%
  • P1849

    Pemetrexed Disodium

    Thymidylate synthase inhibitor, potential SHMT,...

    ≥98%
  • M4100

    MK-0524

    DP1 antagonist.

    ≥99%